Published in J Biol Chem on May 19, 2005
Determination of protein complex stoichiometry through multisignal sedimentation velocity experiments. Anal Biochem (2010) 1.36
A new adaptive grid-size algorithm for the simulation of sedimentation velocity profiles in analytical ultracentrifugation. Comput Phys Commun (2008) 1.35
Using prior knowledge in the determination of macromolecular size-distributions by analytical ultracentrifugation. Biomacromolecules (2007) 1.16
Evaluating the stoichiometry of macromolecular complexes using multisignal sedimentation velocity. Methods (2011) 0.98
A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J Biol Chem (2008) 0.93
Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89
Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J Biol Chem (2009) 0.86
Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem (2011) 0.84
Multi-signal sedimentation velocity analysis with mass conservation for determining the stoichiometry of protein complexes. PLoS One (2013) 0.82
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J (2000) 21.93
Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys J (2002) 5.20
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. Anal Biochem (2003) 5.01
Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci (2002) 4.86
The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci (2000) 3.91
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 3.34
Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation. Proc Natl Acad Sci U S A (2004) 2.74
Structural basis of latency in plasminogen activator inhibitor-1. Nature (1992) 2.33
Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. Methods Enzymol (2004) 2.24
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Vitronectin and its receptors. Curr Opin Cell Biol (1993) 2.17
Structure and biological role of vitronectin. Annu Rev Cell Biol (1991) 2.02
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J (2002) 1.70
Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol (2002) 1.59
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol (2000) 1.58
Boundary problems in the sedimentation and electrophoresis of complex systems in rapid reversible equilibrium. Nature (1956) 1.57
Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest (1997) 1.49
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood (2000) 1.47
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest (2003) 1.42
Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem (2000) 1.40
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40
Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J (1985) 1.38
The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res (1996) 1.34
Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem (1996) 1.31
Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med (2003) 1.28
Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem (1991) 1.21
The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem (1994) 1.18
A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem (1995) 1.16
Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry (1994) 1.15
Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. Surgery (2000) 1.14
Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem (2001) 1.14
Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost (1989) 1.11
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost (2004) 1.11
Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem (2001) 1.10
Interaction of vitronectin with collagen. J Biol Chem (1986) 1.10
The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem (1997) 1.06
Quantitation of spreading factor in human biologic fluids. J Lab Clin Med (1984) 1.04
Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion. J Biol Chem (1993) 1.03
Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood (1987) 1.03
The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) (2002) 1.03
Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem (1997) 1.01
Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem J (1997) 1.00
Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol (2000) 0.99
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer (1998) 0.97
Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol (2000) 0.95
Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol (2002) 0.95
Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry (2003) 0.91
The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol (2004) 0.91
Vitronectin interaction with glycosaminoglycans. Kinetics, structural determinants, and role in binding to endothelial cells. J Biol Chem (1999) 0.90
On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood (1991) 0.90
Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem (1990) 0.89
Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost (1995) 0.88
The solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migration. J Biol Chem (2004) 0.88
Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem (1996) 0.88
Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo. J Biol Chem (1996) 0.87
Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix. J Biol Chem (2002) 0.86
The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin. J Biol Chem (1997) 0.84
Evidence that conformational changes upon the transition of the native to the modified form of vitronectin are not limited to the heparin binding domain. FEBS Lett (1995) 0.83
The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand J Gastroenterol (1997) 0.82
Characterization of the denaturation and renaturation of human plasma vitronectin. II. Investigation into the mechanism of formation of multimers. J Biol Chem (1996) 0.82
Accumulation of type 1 plasminogen activator inhibitor and vitronectin at sites of cellular necrosis and inflammation. Ann N Y Acad Sci (1992) 0.82
Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional. J Biol Chem (1999) 0.82
Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnover. Cell Commun Adhes (2003) 0.82
Attachment of primary neonatal rat astrocytes to vitronectin is mediated by integrins alphavbeta5 and alpha8beta1: modulation by the type 1 plasminogen activator inhibitor. Neurosci Lett (2000) 0.81
Activated vitronectin as a target for anticancer therapy with human antibodies. Cancer Immunol Immunother (2004) 0.81
A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition. Biochemistry (2002) 0.81
New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex. J Biol Chem (2000) 0.80
Binding sites on native and multimeric vitronectin exhibit similar affinity for heparin the influence of self-association and multivalence on ligand binding. Trends Cardiovasc Med (1998) 0.79
Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci (2002) 4.86
Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys J (2006) 4.06
Sedimentation equilibrium analysis of protein interactions with global implicit mass conservation constraints and systematic noise decomposition. Anal Biochem (2004) 3.71
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Studying multiprotein complexes by multisignal sedimentation velocity analytical ultracentrifugation. Proc Natl Acad Sci U S A (2004) 2.74
Recorded scan times can limit the accuracy of sedimentation coefficients in analytical ultracentrifugation. Anal Biochem (2013) 2.57
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
Sedimentation velocity analysis of heterogeneous protein-protein interactions: Lamm equation modeling and sedimentation coefficient distributions c(s). Biophys J (2005) 2.39
Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. Methods Enzymol (2004) 2.24
Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem (2003) 2.19
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
Structure and assembly mechanism for heteromeric kainate receptors. Neuron (2011) 2.03
Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet (2002) 2.02
Sedimentation velocity analysis of heterogeneous protein-protein interactions: sedimentation coefficient distributions c(s) and asymptotic boundary profiles from Gilbert-Jenkins theory. Biophys J (2005) 2.00
Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation. Curr Protoc Immunol (2008) 1.97
High-precision isothermal titration calorimetry with automated peak-shape analysis. Anal Chem (2012) 1.92
Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem (2002) 1.81
A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood (2005) 1.81
Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem (2002) 1.79
On the distribution of protein refractive index increments. Biophys J (2011) 1.76
The N-terminal domain of GluR6-subtype glutamate receptor ion channels. Nat Struct Mol Biol (2009) 1.73
Conformational restriction blocks glutamate receptor desensitization. Nat Struct Mol Biol (2006) 1.67
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J (2006) 1.66
Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation (2008) 1.62
Measuring protein-protein interactions by equilibrium sedimentation. Curr Protoc Immunol (2007) 1.54
Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat Immunol (2003) 1.54
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences. Biochemistry (2004) 1.52
Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J (2010) 1.45
Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest (2002) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest (2003) 1.42
Overview of current methods in sedimentation velocity and sedimentation equilibrium analytical ultracentrifugation. Curr Protoc Protein Sci (2013) 1.41
Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis (2006) 1.40
Cooperative behavior of Escherichia coli cell-division protein FtsZ assembly involves the preferential cyclization of long single-stranded fibrils. Proc Natl Acad Sci U S A (2005) 1.36
A new adaptive grid-size algorithm for the simulation of sedimentation velocity profiles in analytical ultracentrifugation. Comput Phys Commun (2008) 1.35
Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation (2002) 1.34
On the analysis of sedimentation velocity in the study of protein complexes. Eur Biophys J (2009) 1.33
A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol (2005) 1.31
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J (2006) 1.24
Bacteriorhodopsin/amphipol complexes: structural and functional properties. Biophys J (2008) 1.24
Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc Natl Acad Sci U S A (2005) 1.24
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol (2008) 1.24
Inhibition of hemostasis by a high affinity biogenic amine-binding protein from the saliva of a blood-feeding insect. J Biol Chem (2002) 1.23
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest (2009) 1.22
Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem (2008) 1.21
A conformational switch in HP1 releases auto-inhibition to drive heterochromatin assembly. Nature (2013) 1.21
Combined affinity and rate constant distributions of ligand populations from experimental surface binding kinetics and equilibria. Biophys J (2003) 1.21
Analysis of high-affinity assembly for AMPA receptor amino-terminal domains. J Gen Physiol (2012) 1.20
Stability of ligand-binding domain dimer assembly controls kainate receptor desensitization. EMBO J (2009) 1.20
Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteases. J Biol Chem (2011) 1.20
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J Mol Biol (2011) 1.17
Using prior knowledge in the determination of macromolecular size-distributions by analytical ultracentrifugation. Biomacromolecules (2007) 1.16
Eukaryotic RNases H1 act processively by interactions through the duplex RNA-binding domain. Nucleic Acids Res (2005) 1.15
Extended Fujita approach to the molecular weight distribution of polysaccharides and other polymeric systems. Methods (2011) 1.15
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des (2003) 1.14
New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med (Maywood) (2004) 1.14
Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. J Biol Chem (2005) 1.14
Crystal structure of the C-terminal peptidoglycan-binding domain of human peptidoglycan recognition protein Ialpha. J Biol Chem (2004) 1.10
Improving the thermal, radial, and temporal accuracy of the analytical ultracentrifuge through external references. Anal Biochem (2013) 1.10
Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem (2007) 1.09
Autoinhibition of Arf GTPase-activating protein activity by the BAR domain in ASAP1. J Biol Chem (2008) 1.09
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res (2006) 1.08
Energetics of glutamate receptor ligand binding domain dimer assembly are modulated by allosteric ions. Proc Natl Acad Sci U S A (2009) 1.08
Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain (2003) 1.07
Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE (2003) 1.06
Probing the functional heterogeneity of surface binding sites by analysis of experimental binding traces and the effect of mass transport limitation. Biophys J (2006) 1.06
The boundary structure in the analysis of reversibly interacting systems by sedimentation velocity. Methods (2011) 1.05
Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem (2002) 1.04
Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem (2006) 1.04
Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost (2004) 1.04
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain (2012) 1.04
Progressive ankylosis (Ank) protein is expressed by neurons and Ank immunohistochemical reactivity is increased by limbic seizures. Lab Invest (2003) 1.03
Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem (2004) 1.02
Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci (2009) 1.02
PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol (2012) 1.02
Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling. J Biol Chem (2010) 1.01
Regulation of ASAP1 by phospholipids is dependent on the interface between the PH and Arf GAP domains. Cell Signal (2005) 1.00
Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol (2006) 1.00
Analysis of a temperature-sensitive mutant rotavirus indicates that NSP2 octamers are the functional form of the protein. J Virol (2002) 0.99
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med (2004) 0.99
Accounting for solvent signal offsets in the analysis of interferometric sedimentation velocity data. Macromol Biosci (2010) 0.99
Direct interaction of the mouse cytomegalovirus m152/gp40 immunoevasin with RAE-1 isoforms. Biochemistry (2010) 0.99
Global multi-method analysis of affinities and cooperativity in complex systems of macromolecular interactions. Anal Chem (2012) 0.98
A bayesian approach for quantifying trace amounts of antibody aggregates by sedimentation velocity analytical ultracentrifugation. AAPS J (2008) 0.98
Apolipoprotein C-II amyloid fibrils assemble via a reversible pathway that includes fibril breaking and rejoining. J Mol Biol (2008) 0.98
Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost (2004) 0.97
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg (2011) 0.97
Tools for the quantitative analysis of sedimentation boundaries detected by fluorescence optical analytical ultracentrifugation. PLoS One (2013) 0.96
Variable dimerization of the Ly49A natural killer cell receptor results in differential engagement of its MHC class I ligand. J Mol Biol (2006) 0.96
Crystal structure of group A streptococcus Mac-1: insight into dimer-mediated specificity for recognition of human IgG. Structure (2006) 0.96
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes. J Biol Chem (2004) 0.96
The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem (2007) 0.95
Structural, bioinformatic, and in vivo analyses of two Treponema pallidum lipoproteins reveal a unique TRAP transporter. J Mol Biol (2012) 0.94